Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimasartan + HCTZ in Mild to Moderate Hypertension
NCT02222480Phase 2Completed
- Sponsor
- Boryung
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fimasartan in hypertension (HTN) (5 arms), sponsored by Boryung. Primary endpoint: Change of treatment in 24-hour mean systolic blood pressure using ambulatory blood pressure monitoring at 2 weeks. Started Oct 2014; status: completed.
02
Drugs
fimasartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02222480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222480.